Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Interest Income - Total (2021 - 2025)

Historic Interest Income - Total for Abeona Therapeutics (ABEO) over the last 5 years, with Q3 2025 value amounting to $1.7 million.

  • Abeona Therapeutics' Interest Income - Total rose 4062.24% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 2687.85%. This contributed to the annual value of $4.2 million for FY2024, which is 10056.68% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Interest Income - Total stood at $1.7 million, which was up 4062.24% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Interest Income - Total peaked at $1.7 million during Q3 2025, and registered a low of $5000.0 during Q4 2021.
  • In the last 5 years, Abeona Therapeutics' Interest Income - Total had a median value of $593000.0 in 2023 and averaged $636588.2.
  • As far as peak fluctuations go, Abeona Therapeutics' Interest Income - Total surged by 646000.0% in 2022, and later crashed by 1376.99% in 2025.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Interest Income - Total stood at $5000.0 in 2021, then surged by 6460.0% to $328000.0 in 2022, then soared by 126.52% to $743000.0 in 2023, then soared by 37.69% to $1.0 million in 2024, then skyrocketed by 63.44% to $1.7 million in 2025.
  • Its Interest Income - Total stands at $1.7 million for Q3 2025, versus $1.0 million for Q2 2025 and $1.3 million for Q1 2025.